Biotop-report 2013

32

BioTOPics 46 | September 2013 

BioTOP-Report

 Technology Transfer 

Dr. Ulla Peters

UHY Deutschland AG Wirtschaftsprüfungsgesellschaft/Zimmerstraße 23/D-10969 Berlin

Phone [phone]/Fax [phone]/www.uhy-deutschland.de/www.uhy.com

Life sciences companies are in safe hands with UHY.

UHY Deutschland AG is a joint venture of long estab-

lished auditing and consulting firms with a total of 250 

employees and partners.

As a member of UHY International, a global association 

of independent accounting and consulting firms with 

over 7,000 employees we can provide audit, account-

ing, tax and consulting services in 270 business centres 

across the globe.

UHY Deutschland AG has extensive experience in finan-

cial and consulting services for life sciences companies 

for many years. We offer the following services:

 

p

Audits of financial and consolidated statements 

under the German Commercial Code (HGB) and 

IFRS

 

p

Accounting & Reporting

 

p

Due diligence (financial and tax) and business 

valuations

 

p

Consulting services on IPOs

 

p

Business Advisory

 

p

Mergers & Acquisitions (M&A)

 

p

German and international taxation

Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart

Contact

CoLaborator: An incubator space for start-ups 

Alongside many publicly funded initiatives, Bayer HealthCare an-

nounced its concept for a second CoLaborator after San Francisco 

at its Berlin location in May 2013. The new CoLaborator of Bayer 

HealthCare will be established in direct vicinity to the company’s 

own research laboratories and provide suitable premises for rent 

for up to ten bioscience start-ups whose ideas, developments 

and technology platforms match Bayer’s own research activities. 

Internal research at Bayer HealthCare focuses on four core thera-

peutic fields: oncology, cardiology, gynaecology and haematology. 

The project will support the young entrepreneurs in establishing 

their research labs and, if desired, act as their first contact for 

cooperation with industry. The CoLaborator has a building of its 

own with an area of app. 800 sqm, of which some 420 sqm are 

laboratories. 

Prof. Dr. Andreas Busch

Member of the Executive Committee of Bayer 

HealthCare and Head of Global Drug Discovery

Cooperation with academic partners and biotech companies is 

a key element of Bayer HealthCare’s innovation strategy. We 

strongly believe that jointly using the enormous knowledge 

inside and outside the company will help us to get a better 

understanding of major disease mechanisms and to improve 

drug development. The new CoLaborator in Berlin will foster 

communication and cooperation with innovative partners in 

Berlin.

---

Life Sciences from A to Z 

Excellence, Diversity and 

Critical Mass in the Capital 

Region

What are the main projects of the region’s researchers? 

What are their answers to important future challenges 

in the life sciences? 

Stay informed, download BioTOPics45 at:   

www.healthcapital.de/biotechnologie

---

34

BioTOPics 46 | September 2013 

BioTOP-Report

Life Sciences

A Science and Research Hub

Nationally and internationally, Berlin-Brandenburg is regarded as one of the leading life sciences hubs. The 

region offers optimal conditions for this field as a TOP life sciences location with five universities, many higher 

education facilities and a unique extramural research density. Its most prestigious institutions in biotechnology 

and the life sciences include four Max Planck Institutes, four Leibniz Institutes, two Fraunhofer Institutes and 

two centres of the Helmholtz Association. In addition, the region is home to a wide range of hospitals, headed 

by one of the largest university hospitals in Europe, Charité – Universitätsmedizin Berlin. 

From pharmaceutical research, through diagnostics, theranostics 

and molecular genetics, to the development of innovative bio-

materials for medical application, scientists from diverse disci-

plines, including medicine, biology, chemistry, nutrition science, 

bioinformatics, pharmacology and physics, cooperate closely in 

the German capital region. In addition to scientific expertise, Ber-

lin-Brandenburg also offers an excellent infrastructure with its 

wide range of networks and transfer platforms which link univer-

sities, research facilities and users. A new dimension in the trans-

fer of insights from basic into clinical research is now provided 

by the Berlin Institute of Health (BIH) which was opened in June 

2013 and will further enhance the position of the capital region 

as a leading centre for translational and systems medicine. You 

will find more information in this topic on page 36.

Ideas for biobased products of the future

Biotechnology know-how is finding areas of application with con-

siderable potential beyond the healthcare sector. The develop-

ment and production of biomass-based plastics will be in increas-

ing demand in the future and also offers major opportunities for 

the innovation capacity and economic potential of Berlin-Bran-

denburg. Of special importance to this field are the Leibniz In-

APRIL 2012

The Berlin scientist Tatiana Krotkova of Leibniz-Institut für Molekulare Phar-

makologie (FMP) and of NeuroCure cluster of excellence at Charité-Univer-

sitätsmedizin Berlin receives this year's research award for young scientists 

from Human Frontier Science Programs (HFSP) 

++++ 

MDC-researcher Prof. 

Michael Gotthardt and Prof. Norbert Hübner discover a new mechanism for 

myocardial disease in collaboration with colleagues from the USA 

++++ 

A 

10.000 Euro research award of the Deutsche Rheumaliga is awarded to the 

Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)

MAY 2012

Max-Delbrück-Centrum receives multi-million euro funding for a German-

Israeli doctoral training programme 

++++ 

A common matter of the heart for 

140 top scientists: German Centre for Cardiovascular Research 

++++ 

At the 

Institute for Biomaterial Science of Helmholtz-Zentrum Geesthacht in Teltow, 

a new Helmholtz graduate school for macromolecular bioscience is being set 

up  

++++ 

Transatlantic Consortium for Regenerative Medicine founded in Ber-

lin 

++++ 

Charité – Universitätsmedizin Berlin reaches rank 1 of Focus-ranking 

"Germany's best hospital"

JUNE 2012

Charité – Universitätsmedizin Berlin attracts another graduate school in the 

Excellence Initiative: Berlin School of Integrative Oncology 

++++ 

John-Hop-

kins-University and Fraunhofer Heinrich Hertz Institute sign agreement in 

principle to jointly develop medical applications of integrated optical sensors

JULY 2012

1100 years in 100 seconds: The Berlin scientist Leif Schröder at the FMP has 

breakthrough with his group in new diagnosis method 

++++ 

Neuronal stem 

cells destroy brain tumours – MDC and Charité-scientists elucidate new mech-

anism of action

AUGUST 2012

MDC-scientists Dr. Sandrine Sander and Prof. Klaus Rajewsky of MDC Berlin-

Buch discover new key element in formation of Burkitt lymphoma 

++++ 

Ger-

trud Reemtsma Foundation awards HU-biophysicist Peter Hegemann as co-

founder of optogenetics with the Zülch-Preis 2012

SEPTEMBER 2012

Scientists of Charité – Universitätsmedizin Berlin and Labor Berlin succeed in 

deciphering the molecular signature of Hantavirus infection in humans 

++++ 

Graduate school BSRT receives support from the Friede Springer Foundation

OCTOBER 2012

A team of scientists around Anna Flögel of German Institute of Human Nutri-

tion (DifE) and Tobias Pischon of Max-Delbrück-Centrum (MDC) identified 

14 new biomarkers for type-II diabetes which can be the foundation of the 

development of new ways of therapy and prevention for the metabolic dis-

ease. 

++++ 

The World Health Summit brings top-class participants to Berlin 

for the fourth time. 

---